06/10/2025
New research presented at the 2025 PAINWeek conference suggests oral Schedule II ( opioid treatment resulted in higher rates of treatment-emergent adverse events compared with buprenorphine buccal film.
https://www.painmedicinenews.com/a/dDIBAA/f